Papers
2
Total Citations
50
H-Index
2
About
Dr. E. Jason Abel is a urologic oncologist and researcher whose work centers on advancing surgical treatments for kidney cancer, particularly renal cell carcinoma (RCC). His major contributions bridge innovative preclinical techniques and critical real-world outcomes. Notably, he led the first preclinical study of robotically-assisted sonic therapy for renal ablation, demonstrating its feasibility in a live porcine model—a promising step toward non-invasive kidney cancer treatment. In the clinical realm, Dr. Abel spearheaded a multi-institutional analysis of cytoreductive nephrectomy (CN) for metastatic RCC, providing essential contemporary data on peri-operative morbidity and mortality. This work, presented at a major oncology meeting, informs critical risk-benefit discussions for patients considering surgery. His most cited paper (47 citations) highlights his role in pioneering image-guided therapies, while his collaborative clinical studies underscore his commitment to evidence-based urologic oncology. Dr. Abel’s research directly impacts surgical decision-making and the development of less invasive treatment modalities for kidney cancer patients.
Research Focus
Key Achievements
Top Papers
- 1
- 2